Literature DB >> 32773451

Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment.

Christopher Grunseich1, Kenneth H Fischbeck.   

Abstract

PURPOSE OF REVIEW: The aim of this study was to illustrate the current understanding and avenues for developing treatment in spinal and bulbar muscular atrophy (SBMA), an inherited neuromuscular disorder caused by a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene. RECENT
FINDINGS: Important advances have been made in characterizing the molecular mechanism of the disease, including the disruption of protein homeostasis, intracellular trafficking and signalling pathways. Biomarkers such as MRI quantification of muscle volume and fat fraction have been used to track disease progression, and will be useful in future clinical studies. Therapies tested and under development have been based on diverse strategies, including targeting mutant AR gene expression, stability and activity, and pathways that mitigate disease toxicity.
SUMMARY: We provide an overview of the recent advances in understanding the SBMA disease mechanism and highlight efforts to translate these insights into well tolerated and effective therapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32773451      PMCID: PMC7748295          DOI: 10.1097/WCO.0000000000000856

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   6.283


  57 in total

1.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.

Authors:  A R La Spada; E M Wilson; D B Lubahn; A E Harding; K H Fischbeck
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy.

Authors:  Yasuhiro Hijikata; Atsushi Hashizume; Shinichiro Yamada; Tomonori Inagaki; Daisuke Ito; Akihiro Hirakawa; Keisuke Suzuki; Naoki Atsuta; Takashi Tsuboi; Makoto Hattori; Akihiro Hori; Haruhiko Banno; Gen Sobue; Masahisa Katsuno
Journal:  Neurology       Date:  2018-03-23       Impact factor: 9.910

3.  A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.

Authors:  Laura C Bott; Nisha M Badders; Ke-Lian Chen; George G Harmison; Elaine Bautista; Charles C-Y Shih; Masahisa Katsuno; Gen Sobue; J Paul Taylor; Nico P Dantuma; Kenneth H Fischbeck; Carlo Rinaldi
Journal:  Hum Mol Genet       Date:  2016-03-08       Impact factor: 6.150

4.  Preliminary design and validation of the "6-K-scale" for bulbar symptoms evaluation in SBMA.

Authors:  Querin Giorgia; Battel Irene; Mometto Laura; Martinelli Ilaria; Bertolin Cinzia; Pegoraro Elena; Gianni Sorarù
Journal:  Neurol Sci       Date:  2019-03-26       Impact factor: 3.307

5.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

6.  GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.

Authors:  Brian D Freibaum; Yubing Lu; Rodrigo Lopez-Gonzalez; Nam Chul Kim; Sandra Almeida; Kyung-Ha Lee; Nisha Badders; Marc Valentine; Bruce L Miller; Philip C Wong; Leonard Petrucelli; Hong Joo Kim; Fen-Biao Gao; J Paul Taylor
Journal:  Nature       Date:  2015-08-26       Impact factor: 49.962

7.  Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy.

Authors:  Francesco Francini-Pesenti; Giorgia Querin; Cristina Martini; Sara Mareso; David Sacerdoti
Journal:  Acta Myol       Date:  2018-09-01

8.  Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy.

Authors:  Vittoria Lombardi; Giorgia Querin; Oliver J Ziff; Luca Zampedri; Ilaria Martinelli; Carolin Heller; Martha Foiani; Cinzia Bertolin; Ching-Hua Lu; Bilal Malik; Kezia Allen; Carlo Rinaldi; Henrik Zetterberg; Amanda Heslegrave; Linda Greensmith; Michael Hanna; Gianni Soraru; Andrea Malaspina; Pietro Fratta
Journal:  Neurology       Date:  2019-02-20       Impact factor: 9.910

9.  Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.

Authors:  Madoka Iida; Kentaro Sahashi; Naohide Kondo; Hideaki Nakatsuji; Genki Tohnai; Yutaka Tsutsumi; Seiya Noda; Ayuka Murakami; Kazunari Onodera; Yohei Okada; Masahiro Nakatochi; Yuka Tsukagoshi Okabe; Shinobu Shimizu; Masaaki Mizuno; Hiroaki Adachi; Hideyuki Okano; Gen Sobue; Masahisa Katsuno
Journal:  Nat Commun       Date:  2019-09-19       Impact factor: 14.919

10.  Trehalose alleviates the phenotype of Machado-Joseph disease mouse models.

Authors:  Magda M Santana; Susana Paixão; Janete Cunha-Santos; Teresa Pereira Silva; Allyson Trevino-Garcia; Laetitia S Gaspar; Clévio Nóbrega; Rui Jorge Nobre; Cláudia Cavadas; Hagar Greif; Luís Pereira de Almeida
Journal:  J Transl Med       Date:  2020-04-09       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.